Table 1 Clinical characteristics of 137 relapsed pediatric BCP-ALL patients that were CIMP classified at ALL diagnosis
Relapsed BCP-ALL patients | CIMP− n = 42 | CIMP+ n = 95 | p value |
|---|---|---|---|
Sex male/female | 28/14 | 51/44 | ns |
Age at primary diagnosis (months) | 48 | 70 | ns |
(median, range) | (16–185) | (12–211) | |
WBC × 109/l at primary diagnosis | 20,7 | 18,6 | ns |
(median, range) | (2,2–269) | (1,3–274) | |
Cytogenetics at primary diagnosis | 0.021 | ||
Favorablea | 18 (43%) | 50 (53%) | |
Unfavorableb | 11 (26%) | 8 (8%) | |
Otherc | 13 (31%) | 37 (39%) | |
Initial risk group at primary diagnosisd | ns | ||
SR/IR | 23 (55%) | 64 (67%) | |
HR | 19 (45%) | 31 (33%) | |
Relapse sitee | 0.077 | ||
Bone marrow isolated (iBM) | 31 (74%) | 50 (53%) | |
Combined (iBM and iEM) | 6 (14%) | 24 (26%) | |
Extramedullary (iEM) | 5 (12%) | 20 (21%) | |
Time to relapse (median, months) | 29,5 | 35 | ns |
(Range) | (5–124) | (1–172) | |
Very early (VE) | 11 (26%) | 12 (13%) | |
Early (E) | 16 (38%) | 38 (40%) | |
Late (L) | 15 (36%) | 45 (47%) | |
IntReALL risk class at relapse (relapse site/time to relapse) | 0.021 | ||
Standard risk (L-iBM, iEM, Comb, E-iEM, Comb) | 21 (50%) | 67 (71%) | |
High risk (VE-iBM, iEM, Comb, E-iBM) | 21 (50%) | 28 (29%) | |
HSCT after relapse | ns | ||
Yes | 15 (36%) | 43 (45%) | |
No | 27 (64%) | 52 (55%) | |
pOS5years | 0.33+/−0.08 | 0.65+/−0.05 | 0.001 |